Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience AB (LTS:0RK9) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alligator Bioscience AB EBITDA Margin % Related Terms
Alligator Bioscience AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RK9 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (LTS:0RK9) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #823 out of 939 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Alligator Bioscience AB's EBITDA Margin % too high?
Alligator Bioscience AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Alligator Bioscience AB ranks #823 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alligator Bioscience AB has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #823 out of 939 companies for EBITDA Margin %. This places Alligator Bioscience AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (LTS:0RK9) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.19 — trading 1792% above its estimated fair value. The current EBITDA Margin % is 0.00%. Alligator Bioscience AB's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alligator Bioscience AB (LTS:0RK9), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alligator Bioscience AB (LTS:0RK9) Overvalued in 2026?
Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued.
The current stock price of kr0.19 is trading 1792% above its estimated GF Value™ of kr0.01.
GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.
Key valuation signals for LTS:0RK9:
EBITDA Margin %: 0.00%
GF Value™: kr0.01 vs. price of kr0.19 (1792% above fair value)
No single metric tells the full story. See the LTS:0RK9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
42GF Score
Get the complete analysis for LTS:0RK9
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RK9 has been successfully added to your 
